Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

how do peptide fold? | LifeTein Peptide Blog

Short Peptide Folding How does the amino acid sequence of a protein chain determine and maintain its 3D folded state? How do small proteins fold? Short Peptide Folding Many small proteins or miniproteins are peptides shorter than 40-50 residues with stable fol

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Short Peptide Folding

How does the amino acid sequence of a protein chain determine and maintain its 3D folded state? How do small proteins fold?

Short Peptide Folding

Many small proteins or miniproteins are peptides shorter than 40-50 residues with stable folding that contain secondary structure elements such as alpha helices and beta strands.

An autonomously folding, 35-residue, thermostable subdomain (HP36) of the villain headpiece is the smallest folded domain of a naturally occurring protein. Polypeptides simplify the protein-folding problem. They allow in-depth examinations of sequence-structure-stability relationships without using the complex larger proteins.

In this recent study, Rocklin et al. designed sequences intended to fold into desired structures. The novel proteins may be helpful in bioengineering or pharmacological applications.

Check the paper from here: https://goo.gl/Tregb7

http://science.sciencemag.org/content/357/6347/168

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Research context

Read sources and limitations before applying a claim.

Case Studies and Examples

One notable example is the development of a peptide-based vaccine for the H1N1 influenza virus. Researchers have identified a killer decapeptide (KP) with potent action against the virus. When combined with PADRE, this vaccine has shown improved efficacy in reducing viral levels and improving survival rates in animal models. Applications in Autoimmune Diseases Modulating Immune Responses The PADRE peptide has shown potential in the treatment of autoimmune diseases by modulating immune responses. In conditions such as rheumatoid arthritis and multiple sclerosis, the immune system mistakenly attacks the body’s own tissues. By incorporating PADRE into therapeutic strategies, researchers aim to redirect the immune response, reducing inflammation and tissue damage. Preclinical and Clinical Studies Preclinical studies have demonstrated that PADRE can induce regulatory T-cells (Tregs), which play a crucial role in maintaining immune tolerance. These findings have paved the way for clinical trials exploring PADRE-based therapies for autoimmune diseases. Early results indicate that PADRE can help restore immune balance, offering a promising avenue for treatment. Applications in Allergy Treatments Reducing Allergic Reactions In allergy treatments, the PADRE peptide is used to reduce hypersensitivity reactions. By enhancing the immune system’s ability to tolerate allergens, PADRE can help mitigate symptoms associated with allergic conditions such as asthma and food allergies. Immunotherapy Approaches Immunotherapy approaches incorporating PADRE have shown efficacy in desensitizing patients to specific allergens. For example, PADRE-based vaccines targeting peanut allergies have demonstrated the ability to reduce allergic reactions in clinical trials. These vaccines work by gradually exposing the immune system to the allergen in a controlled manner, promoting tolerance.Find the PADRE Peptide here. Future Directions and Research Expanding Therapeutic Applications Ongoing research aims to expand the therapeutic applications of the PADRE peptide. Scientists are exploring its potential in areas such as transplantation medicine, where PADRE could help prevent organ rejection by modulating the immune response. Additionally, PADRE is being investigated for its role in enhancing the efficacy of DNA vaccines and mRNA vaccines, which have gained prominence in recent years. Innovative Delivery Systems Innovative delivery systems are being developed to improve the stability and efficacy of PADRE-based therapies. These include nanoparticle-based delivery and liposomal formulations, which can enhance the bioavailability and targeted delivery of PADRE to specific tissues. Frequently Asked Questions What is the primary function of the PADRE peptide? The primary function of the PADRE peptide is to bind to MHC class II molecules, enhancing the activation of helper T-cells and boosting immune responses. How is PADRE used in cancer immunotherapy? In cancer immunotherapy, PADRE is incorporated into peptide-based vaccines to improve the presentation of tumor antigens to the immune system, leading to a more effective anti-tumor response. Can PADRE be used in the treatment of autoimmune diseases? Yes, PADRE has shown potential in modulating immune responses in autoimmune diseases, helping to reduce inflammation and tissue damage. What are some examples of PADRE’s applications in allergy treatments? PADRE is used in immunotherapy approaches to reduce allergic reactions, such as in vaccines targeting peanut allergies, which promote immune tolerance to the allergen. What future research directions are being explored for PADRE? Future research is exploring PADRE’s potential in transplantation medicine, DNA and mRNA vaccines, and innovative delivery systems like nanoparticle-based and liposomal formulations.

Source: lifetein.com ↗

Structural Studies

Rigid spacers help stabilize peptide conformations in NMR or crystallography studies, providing more precise structural data.Find out more about peptide synthesis here.

Source: lifetein.com ↗
Practical and safety references

These excerpts are educational, not personalised medical instructions.

How-to reference

How to solubilize my synthetic peptides? #

Please refer to this FAQ for details: Handling and Storage of Synthetic Peptides. If the peptides are still cloudy, or turbid, you may have reached the limit of solubility. When the peptides are insoluble in the buffer, please try to sonicate, centrifuge, and lyophilize the peptide. Make sure to break the lyophilized lumps into a fine powder. Then try a small volume of a good agent 8M Urea, NMP, DMF, or DMSO to dissolve the peptide. Then dilute with water or your desired buffer. For peptides with Arg or LYs, you should try to lower the pH to 6 because the protonated amino acids will help solubility. Sonication and the following solvents may help with difficult peptides: 1) Begin with 100 % acetonitrile then dilute with water until 50% 2) Begin with 100% DMSO then dilute with water until 30 % 3) Dissolve it with 8M Urea 4) Dissolve it with 6 or 8 M Guanidine hydrochloride 5) 6M GuHCL, 0.05% TFA, pH2, 6) 100% TFA 7) 40% AcOH, 30%ACN, 30% water

Source: lifetein.com ↗
Storage reference

Storage temperatures and conditions #

For many of our antibodies, freezing at -20 C or -80 C in small aliquots is the optimal storage condition. Aliquotting minimizes damage due to freezing and thawing, as well as contamination introduced by pipetting from a single vial multiple times. Aliquots should be no smaller than 10 µl. Upon receiving the antibody, centrifuge at 5,000 x g for 30 seconds to pull down the solution, and transfer aliquots into low-protein-binding microcentrifuge tubes. Antibodies should be frozen as soon as possible, storage at 4 C upon receipt of the antibody is acceptable for one to two weeks, followed by freezing for long-term storage. To prevent microbial contamination, sodium azide can be added to an antibody preparation to a final concentration of 0.02% (w/v). If using antibodies for in vivo studies, please be sure to use preparations that do not contain sodium azide. This antimicrobial agent blocks the cytochrome electron transport system. Sodium azide will interfere with any conjugation that involves an amine group and should be removed before proceeding with the conjugation. After conjugation, antibodies can be stored in sodium azide but 0.01% thimerosal (Merthiolate), which does not have a primary amine, is an acceptable alternative. Sodium azide can be removed from antibody solutions by dialysis or gel filtration. The molecular weight of IgG is 150,000 daltons (IgM is ~ 600,000); the molecular weight of sodium azide is 65 daltons. A micro-dialysis unit with a cut off at 14,000 dalt…

Source: lifetein.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →